One of the challenges facing both the domestic and international pharmaceutical industries is the limited selection and suboptimal efficacy of available antiviral drugs. The high mutational variability of influenza viruses contributes to rapid acquisition of drug resistance, which diminishes or nullifies the effectiveness of existing therapies, thereby necessitating the exploration for novel therapeutics.